What is he best known for?
The fields of study he is best known for:
Masabumi Shibuya mostly deals with Vascular endothelial growth factor, Vascular endothelial growth factor A, Angiogenesis, Receptor tyrosine kinase and Tyrosine kinase.
Masabumi Shibuya is investigating Cancer research and Internal medicine as part of his examination of Vascular endothelial growth factor.
The concepts of his Vascular endothelial growth factor A study are interwoven with issues in Blood vessel, Signal transduction and Growth factor.
His research integrates issues of Vasculogenesis, Aniridia, Pathology, Cornea and Fibroblast growth factor in his study of Angiogenesis.
The study incorporates disciplines such as Tropomyosin receptor kinase C and Platelet-derived growth factor receptor in addition to Receptor tyrosine kinase.
As a part of the same scientific family, Masabumi Shibuya mostly works in the field of Tyrosine kinase, focusing on Endothelial stem cell and, on occasion, Endothelium.
His most cited work include:
- Nucleotide sequence and expression of a novel human receptor-type tyrosine kinase gene (flt) closely related to the fms family. (1031 citations)
- D-type cyclin-dependent kinase activity in mammalian cells. (1000 citations)
- Flt-1 lacking the tyrosine kinase domain is sufficient for normal development and angiogenesis in mice (967 citations)
What are the main themes of his work throughout his whole career to date?
His primary areas of investigation include Vascular endothelial growth factor, Cancer research, Angiogenesis, Cell biology and Molecular biology.
His Vascular endothelial growth factor research is multidisciplinary, relying on both Endocrinology and Growth factor.
His Cancer research research focuses on subjects like Immunology, which are linked to Haematopoiesis and Macrophage.
He works mostly in the field of Angiogenesis, limiting it down to topics relating to Tyrosine kinase and, in certain cases, Tyrosine phosphorylation, as a part of the same area of interest.
His Cell biology research includes elements of Embryonic stem cell and Biochemistry.
His studies in Molecular biology integrate themes in fields like Cell culture, Protein kinase A and Complementary DNA, Peptide sequence, Gene.
He most often published in these fields:
- Vascular endothelial growth factor (39.43%)
- Cancer research (37.85%)
- Angiogenesis (36.28%)
What were the highlights of his more recent work (between 2008-2016)?
- Angiogenesis (36.28%)
- Cancer research (37.85%)
- Vascular endothelial growth factor (39.43%)
In recent papers he was focusing on the following fields of study:
Angiogenesis, Cancer research, Vascular endothelial growth factor, Internal medicine and Vascular endothelial growth factor A are his primary areas of study.
His Angiogenesis study integrates concerns from other disciplines, such as Endothelial stem cell, Lymphangiogenesis, Tyrosine kinase, Receptor and Cell biology.
His Cancer research study combines topics in areas such as Hypoxia, Cancer cell, Immunology, Tumor progression and In vivo.
Masabumi Shibuya mostly deals with Vascular endothelial growth inhibitor in his studies of Vascular endothelial growth factor.
His study in Internal medicine is interdisciplinary in nature, drawing from both Apoptosis, Endocrinology and Haematopoiesis, Stem cell.
His work in the fields of Vascular endothelial growth factor A, such as Vascular endothelial growth factor B and Kinase insert domain receptor, overlaps with other areas such as Postpartum period.
Between 2008 and 2016, his most popular works were:
- M-CSF inhibition selectively targets pathological angiogenesis and lymphangiogenesis (288 citations)
- The spatiotemporal development of adipose tissue (118 citations)
- Klotho is associated with VEGF receptor-2 and the transient receptor potential canonical-1 Ca2+ channel to maintain endothelial integrity. (107 citations)
In his most recent research, the most cited papers focused on:
Masabumi Shibuya spends much of his time researching Angiogenesis, Cancer research, Endocrinology, Internal medicine and Vascular endothelial growth factor A.
As part of one scientific family, Masabumi Shibuya deals mainly with the area of Angiogenesis, narrowing it down to issues related to the Vascular endothelial growth factor B, and often Combination therapy, Receptor, Central nervous system, Vascular endothelial growth factor C and Neuropilin 1.
Masabumi Shibuya is studying Vascular endothelial growth factor, which is a component of Cancer research.
His studies deal with areas such as Tyrosine kinase and Mesenchymal stem cell, Cell biology as well as Endocrinology.
His study in the fields of Adipocyte, 3T3-L1 and Transient receptor potential channel under the domain of Internal medicine overlaps with other disciplines such as Adipose tissue macrophages.
Masabumi Shibuya combines subjects such as Cancer cell, Growth factor and Vascular permeability with his study of Vascular endothelial growth factor A.
This overview was generated by a machine learning system which analysed the scientist’s
body of work. If you have any feedback, you can
contact us
here.
